Acción CYTO ALTAMIRA THERAPEUTICS LTD.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Altamira Therapeutics Ltd.

Acciones

CYTO

BMG0360L1349

Precio de cierre Nasdaq
Otros sitios de cotización
 00:00:00 03/05/2024 		Varia. Cinco días. Varia. 1 de enero.
1,64 USD +1,23 % Gráfico intradía de Altamira Therapeutics Ltd. -2,96 % -52,87 %
01/05 Altamira Therapeutics Ltd. Anuncia la presentación de una solicitud de patente provisional para nanopartículas OligoPhore con siRNA dirigido a la proteína p65 en el tratamiento del cáncer y la inflamación CI
24/04 Altamira Therapeutics Ltd. anuncia la publicación de los resultados positivos del ensayo de Bentrio en la rinitis alérgica estacional en una revista de primera línea revisada por expertos CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
Altamira Therapeutics Ltd. Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
Altamira Therapeutics Ltd. Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
Altamira Therapeutics : Notice of the Annual General Meeting of Shareholders of Altamira Therapeutics Ltd. (the “Company”) to be held on May 16, 2024 - Form 6-K
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
Altamira Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
Sector Update: Health Care Stocks Decline Late Afternoon
Top Midday Gainers
Sector Update: Health Care Stocks Softer in Afternoon Trading
Altamira, Univercells Partner to Test mRNA Vaccine Delivery; Shares Surge
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
Altamira Therapeutics Ltd. Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
Altamira Therapeutics? Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
Altamira Files Second Provisional Patent Application in Cancer Treatment; Shares Rise
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción CYTO
  4. Noticias Altamira Therapeutics Ltd.
  5. Otros idiomas